The Swiss company, which markets Elevidys abroad, said it believes the benefit-risk balance to treatment remains positive in ...

The French biotech is developing a new drug approach in a disease market that’s projected to grow to $30 billion by 2030.

The startup is using elements of gene and cell therapy to create medicines that could be useful against an array of tough-to-treat solid tumors.

George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...